Antiarrhythmic Effect of Statin Therapy and Atrial FibrillationA Meta-Analysis of Randomized Controlled Trials
Laurent Fauchier, MD, PhD*,
Bertrand Pierre, MD,
Axel de Labriolle, MD,
Caroline Grimard, MD,
Noura Zannad, MD and
Dominique Babuty, MD, PhD
Cardiologie, Centre Hospitalier Universitaire Trousseau, Tours, France.
View larger version (7K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Funnel Plot of the Meta-Analysis
Review: statins versus placebo or control regimen for the end point of first episode (new-onset or post-operative) or recurrence of atrial fibrillation (AF). Funnel plot allows assessment of publication bias. Bias is suspected if the plots are asymmetric on each side of the dashed line. Present plot shows no clear evidence of bias. OR = odds ratio.
|
|
View larger version (22K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Effect of Statins on the Occurrence of AF
Effect of statins versus placebo or control regimen on the occurrence of all types of atrial fibrillation (AF) (i.e., first episode or recurrence of AF, top panel), primary prevention of AF (new-onset or post-operative AF, middle panel), or prevention of recurrence of AF (lower panel). MIRACL 1 and 2 indicate the effect of statin in subgroups of patients in the MIRACL study without or with a previous AF, respectively. CI = confidence interval; OR = odds ratio.
|
|
View larger version (8K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 4 Effect of Atorvastatin on the Occurrence of AF
Effect of atorvastatin versus placebo or control regimen on the occurrence of first AF episode (new-onset or post-operative AF) or recurrence of AF. Abbreviations as in Figure 3.
|
|
|
3